Life Sciences Partners, the pan-European life science venture capital group, has announced the IPO of BioXell, its Italian-based portfolio company, on the main board of the Swiss Stock Exchange.
In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.
Become a Premium SubscriberIf you are already a AltAssets subscriber please log in below.